Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191060 | 0.94 | EGFR (0.41) | KCNJ1EGFRPTK2PTGS1PTGS2 | |
| SCHEMBL20144423 | 0.91 | BCHE (0.36) | KCNJ1EGFRPTK2PTGS1PTGS2 | |
| SCHEMBL9798631 | 0.87 | EGFR (0.34) | KCNJ1EGFRPTK2PTGS1PTGS2 | |
| SCHEMBL20144407 | 0.87 | BCHE (0.42) | KCNJ1EGFRPTK2PTGS1PTGS2 | |
| SCHEMBL13840466 | 0.83 | KCNJ1 (0.33) | KCNJ1EGFRPTK2PTGS1PTGS2 | |
| SCHEMBL17408868 | 0.79 | KCNJ1 (0.34) | KCNJ1HTR2B | |
| SCHEMBL20135774 | 0.79 | KCNJ1 (0.33) | KCNJ1 | |
| SCHEMBL16948187 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL20144422 | 0.79 | — | — | |
| SCHEMBL2023434 | 0.75 | ERN1 (0.49) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513072-A1 | PYRAZINE DERIVATIVES,PROCESS FOR MANUFACTURE AND USE THEREOF | Ji Nan University (CN) | 2012-10-24 | — | — | EP | claimed |
| US-20120115874-A1 | PYRAZINE DERIVATIVES, PROCESS FOR MANUFACTURE AND USE THEREOF | JINAN UNIVERSITY (CN) | 2012-05-10 | — | — | US | claimed |
| WO-2012003784-A1 | PYRAZINE DERIVATIVES,PROCESS FOR MANUFACTURE AND USE THEREOF | JINAN UNIVERSITY (CN) | 2012-01-12 | — | — | WO | claimed |
| EP-3321259-B1 | NEW PYRAZINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-3321259-B1 | NEW PYRAZINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-3143002-B1 | COMPOUNDS WITH NEURAL PROTECTIVE EFFECT, AND PREPARATION AND USE THEREOF | GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-10703729-B2 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2020-07-07 | — | — | US | disclosed |
| US-10703729-B2 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20190276413-A1 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190276413-A1 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| EP-3321259-A1 | NEW PYRAZINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Guangzhou Magpie Pharmaceutical Co., Ltd. (CN) | 2018-05-16 | — | — | EP | disclosed |
| WO-2015109935-A1 | COMPOUNDS WITH NEURAL PROTECTIVE EFFECT, AND PREPARATION AND USE THEREOF | GUANGZHOU MAGPIE PHARMACEUTICAL CO., LTD (CN) | 2015-07-30 | — | — | WO | disclosed |
| CN-102311396-B | Pyrazine derivative and preparation method as well as application thereof to pharmacy | UNIV JINAN | 2015-01-07 | — | — | CN | disclosed |
| US-8796281-B2 | Lighting device having at least one heat sink | JINAN UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-8796281-B2 | Lighting device having at least one heat sink | JINAN UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| CN-103301132-A | Ligustrazine secondary-alcohol and tertiary-alcohol derivative and application for same in pharmacy | UNIV NANJING CHINESE MEDICINE | 2013-09-18 | — | — | CN | disclosed |
| EP-2513072-A1 | PYRAZINE DERIVATIVES,PROCESS FOR MANUFACTURE AND USE THEREOF | Ji Nan University (CN) | 2012-10-24 | — | — | EP | disclosed |
| US-20120115874-A1 | PYRAZINE DERIVATIVES, PROCESS FOR MANUFACTURE AND USE THEREOF | JINAN UNIVERSITY (CN) | 2012-05-10 | — | — | US | disclosed |
| US-20120115874-A1 | PYRAZINE DERIVATIVES, PROCESS FOR MANUFACTURE AND USE THEREOF | JINAN UNIVERSITY (CN) | 2012-05-10 | — | — | US | disclosed |
| WO-2012003784-A1 | PYRAZINE DERIVATIVES,PROCESS FOR MANUFACTURE AND USE THEREOF | JINAN UNIVERSITY (CN) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276413-A1 | Pyrazine derivative, and preparation method and medical use thereof | RYR2, RYR1, ORAI1 | KCNJ1 134/4885EGFR 4794/4885PTK2 1770/4885 |
| US-20120115874-A1 | PYRAZINE DERIVATIVES, PROCESS FOR MANUFACTURE AND USE THEREOF | F3, F12, PC | KCNJ1 806/4885EGFR 3338/4885PTK2 2312/4885 |
| US-10703729-B2 | Pyrazine derivative, and preparation method and medical use thereof | RYR2, RYR1, ORAI1 | KCNJ1 134/4885EGFR 4794/4885PTK2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.